Skyline will use TrovaGene's nucleophosmin protein mutation, which is found in around 35 percent of acute myeloid leukemia patients and is associated with good disease prognosis, in its Affymetrix-manufactured AMLprofiler in vitro diagnostic.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
